Interleukin-1 in the treatment of cancer.
Interleukin-1 (IL-1) is a cytokine with many activities central to immune function and hematopoiesis. Many IL-1 properties can be potentially exploited in the treatment of malignancy. This review describes the toxicities and antitumor effects observed in Phase I and II trials of IL-1 in cancer patients. The immunophysiology and the induction of cytokines by IL-1 has been examined in many of the Phase I trials and has aided in understanding IL-1 effects in humans. The influence of IL-1 on granulopoiesis and thrombopoiesis when given by different regimes is also reviewed in detail.
Curti
B D
BD
Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21701, USA.
Smith
J W
JW
D000818:Animals; D016026:Bone Marrow Transplantation; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D007375:Interleukin-1